Brief: Eql Pharma AB Says Qtrly EBIT Amounted To SEK 9.8 (15.5) Million, A Decrease Of 37%

EQL Pharma AB

13/02/2024 17:47

Feb 13 (Reuters) - EQL Pharma AB  EQL.TE :
    * QTRLY EBIT AMOUNTED TO SEK 9.8 (15.5) MILLION, A DECREASE
OF
37%. OPERATING MARGIN WAS 14% (19%).
    * EARNINGS PER SHARE BEFORE DILUTION WERE SEK 0:22 (0:41)
FOR
QUARTER. EARNINGS PER SHARE AFTER DILUTION WERE 0:22 (0:40).
    * QTRLY EBITDA MARGIN WAS 17%
    * LONG-TERM FINANCIAL GOALS REMAIN UNCHANGED, AS DOES SALES
FORECAST FOR FULL YEAR 2023/24

Source text for Eikon:  ID:nWkrb9JbX5 
Further company coverage:  EQL.TE 

 ((Reuters.Briefs@thomsonreuters.com;))